SAN ANTONIO--(BUSINESS WIRE)-- GenSpera, Inc. (OTC.BB: GNSZ) announced that the
United States Patent and Trademark Office (USPTO) issued patent 8,450,280
"Activation of Peptide Prodrugs by HK2." The patent covers the composition of a
series of prodrugs activated by HK2 to deliver a thapsigargin derivative
selectively to prostate cancers. HK2 is an enzyme secreted by prostate cancer
cells. A derivative of thapsigargin, 12ADT, is the active component of G-202,
GenSpera's lead drug candidate in Phase II clinical trials for liver cancer
after sorafenib (Nexavar(R)) therapy.
"The issuance of this patent further strengthens our intellectual property
position for targeted anti-cancer prodrugs and recognizes their unique
applicability in treating prostate cancer," commented GenSpera CEO, Craig
Dionne, Ph.D. "It is important that we continue to expand and defend our
thapsigargin prodrug research and development in areas of high unmet medical
needs and commercial opportunities."
GenSpera's technology platform combines a powerful, plant-derived cytotoxin
(thapsigargin) with a prodrug delivery system that provides for the targeted
release of drug candidates within a tumor. Unlike typical chemotherapeutic
agents, thapsigargin results in cell death irrespective of the rate of cell
division, which may provide an effective approach to kill both fast- and
slow-growing cancers. GenSpera's lead drug candidate, G-202, is activated by the
enzyme PSMA which is found at high levels in liver and prostate cancer and in
the vasculature of almost all other solid tumors and is therefore expected to
have efficacy in a wide variety of tumor types.
Data from the G-202 Phase Ib program in solid tumor patients demonstrated that
G-202 is well-tolerated with prolonged disease stabilization observed in several
hepatocellular carcinoma (liver cancer) patients whose disease had previously
worsened on standard therapy. A Phase II clinical trial in patients with
hepatocellular carcinoma is currently underway.
For more information, please visit the Company's website: www.genspera.com or
follow us on Twitter @GenSperaNews.
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements. Investors are
cautioned that such forward-looking statements in this press release regarding
potential applications of GenSpera's technologies constitute forward-looking
statements that involve risks and uncertainties, including, without limitation,
risks inherent in the development and commercialization of potential products,
uncertainty of clinical trial results or regulatory approvals or clearances,
need for future capital, dependence upon collaborators and maintenance of our
intellectual property rights. Actual results may differ materially from the
results anticipated in these forward-looking statements. Additional information
on potential factors that could affect our results and other risks and
uncertainties will be detailed from time to time in GenSpera's periodic reports
filed with the Securities and Exchange Commission.
Craig Dionne, Ph.D., 210-479-8112
Paul Henning, 212-554-5462
Deanne Eagle, 917-837-5866
Source: GenSpera, Inc.